Q-omics provides the consensus-scored USP27X profile across patient tissues and cancer cell-line models. USP27X expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, USP27X is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, USP27X RNA expression shows 20,117 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where USP27X shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP27X — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP27X survival associations across molecular data types. USP27X RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP27X RNA expression–survival associations across cancer types. High USP27X expression shows unfavorable associations in LIHC, KIRP and KICH, but favorable associations in KIRC, ACC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for USP27X RNA expression.
This table summarizes USP27X tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for USP27X. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP27X shows lower tumor expression in KICH and UCEC and higher tumor expression in COAD, KIRC, HNSC and LIHC. The COAD box plot shows higher USP27X RNA expression in tumor versus normal tissue (log2 FC = +0.752, t-test p < 0.001).
This table shows molecular features associated with USP27X in patient tissues and cancer cell lines. In patient samples, USP27X shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, USP27X RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
